Partner
About Stabicon

Proven molecules. Engineered for real-world efficacy.

At Stabicon, we transform proven ingredients into high-performance, bioavailable therapeutic platforms. Built on pharmaceutical expertise, we focus on enhancing absorption, optimizing delivery, and enabling scalable, multi-format solutions – so our partners can launch clinically effective, differentiated products that truly deliver results.

Our Belief

“We believe proven molecules should deliver real results – built on science, simplicity, and scalability.”

Leadership & Expertise

Stewardship rooted in forty plus years of pharmaceutical credibility.

Chairman

Mr. C.P. Bothra

Mr. Chandanmal Pukhraj Bothra is a distinguished pharmaceutical entrepreneur and industry veteran with over five decades of experience spanning pharmaceutical manufacturing, research, commercialization, healthcare services and global business development. Widely recognised for his vision and leadership, he has played a transformative role in shaping the growth of the Indian pharmaceutical industry and building globally respected healthcare enterprises. As co-founder and long-time Managing Director of Medreich Limited, he transformed the company into a leading global Contract Research and Manufacturing Services (CRAMS) organization, partnering with multinationals including Pfizer, Novartis, Sanofi and GlaxoSmithKline, and expanding across Europe, Africa, Asia and Australia – culminating in its landmark acquisition by Meiji Seika Pharma of Japan in 2015, the first 100% acquisition of an Indian pharmaceutical company by a Japanese pharmaceutical major. His expertise spans the entire pharmaceutical value chain – R&D, regulatory strategy, manufacturing, quality systems and international business. Following Medreich, he founded and nurtured several healthcare ventures including Lyrus Life Sciences, Stabicon Life Sciences, VERISTOnN Sciences and Trust Chemists & Druggists, forming an integrated healthcare ecosystem. Deeply committed to advancing healthcare access, education and social impact, his contributions have earned recognitions including Udyog Patra, Udyog Ratan, Bharatiya Udyog Jyoti and Udyog Vibhushan.

Director

Mr. P. Krishnamurthy

A distinguished pharmaceutical professional with over four decades of experience spanning pharmaceutical research, analytical sciences, product development, quality systems, regulatory affairs and technical operations. He holds a postgraduate degree in Pharmaceutical Chemistry with distinction and has built an illustrious career advancing pharmaceutical quality and regulatory excellence across India and global markets. Widely recognised as an authority in pharmaceutical analytical sciences, he has designed and established eleven world-class analytical laboratories meeting stringent international regulatory expectations. He has been instrumental in securing approvals from MHRA (UK), TGA (Australia), South African health authorities, France, Ukraine and numerous agencies across Africa and the Middle East, and as Head of International Regulatory Affairs led the preparation and submission of more than 4,000 product dossiers globally. A passionate educator and mentor, he serves as faculty at pharmaceutical training institutions, trains newly recruited Drug Inspectors with the Karnataka Drugs Control Department, and contributes to the Indian Pharmacopoeia Commission.

Director

Mrs. Kushboo Ranka

A dynamic entrepreneur and business leader with extensive experience across finance, healthcare, wellness and pharmaceutical sectors. As Director of Stabicon Life Sciences, she has been instrumental in shaping the company's strategic direction, driving sustainable growth and establishing a strong foundation for innovation-led expansion. Under her leadership, Stabicon has evolved into a profitable, innovation-focused organization, developing differentiated products and forging strategic partnerships with several leading multinational corporations. During the COVID-19 pandemic she ensured uninterrupted supply of essential immunity and wellness products, and she spearheaded Stabicon's expansion into the nutraceutical and wellness segment with a strong pipeline of market-ready products. Beyond her corporate responsibilities, she is actively involved in philanthropic and community development initiatives and serves as a Trustee of CPBT.

Head – Operations

Mr. Sumit Kumar Jain

An accomplished pharmaceutical professional with over 17 years of experience in analytical research, quality control, stability sciences and pharmaceutical operations. He holds a postgraduate degree in Pharmaceutical Chemistry with distinction and brings extensive expertise in analytical method development, validation, product characterization and laboratory operations. Prior to Stabicon he held key positions with Torrent Pharmaceuticals, Piramal Healthcare, Novartis and GlaxoSmithKline (GSK), spanning the development and characterization of New Chemical Entities, stability studies and product development for innovator, generic and OTC formulations. A recognised subject-matter expert in stability sciences and R&D quality systems, he has successfully supported numerous international regulatory inspections and customer audits including the US FDA, WHO Geneva and Netherlands agencies. At Stabicon he oversees operational excellence across analytical services, quality systems, laboratory management and project execution, and is passionate about mentoring teams and fostering professional growth.

Head – Innovation

Mrs. Jyolsna Agnes Jose

A highly respected life sciences and wellness industry professional with over 25 years of experience spanning product innovation, formulation development, business strategy, research, development and operations. She leads the Innovation Division at Stabicon, spearheading the company's nutraceutical, wellness and natural-products initiatives. Since joining Stabicon in 2020 she has driven innovation-led growth through new product development, platform technology creation and customer-centric formulation solutions. She has contributed to the development of more than 300 formulations for customers across international markets, with in-depth knowledge of FSSAI, AYUSH, DSHEA, TGA, EFSA and regulations across the US, UK, Australia, South Africa, the Middle East and Southeast Asia. Previously a founding member of the Formulation R&D team at Sami Labs / Sabinsa (14 years), and later Head – R&D at Maven iLab, with earlier roles at Micro Labs and Medreich. A Pharmacy graduate from Bangalore University, she has authored research publications in national and international scientific journals.

Our Journey

From 1976 to today – pioneering Indian pharma milestones.

1976

The journey began with the formation of Kanpha Labs.

1976
01 / 12
2025
  • 1976
  • 1987
  • 1994
  • 1998
  • 2006
  • 2010
  • 2015
  • 2016
  • 2018
  • 2023
  • 2024
  • 2025
1976. The journey began with the formation of Kanpha Labs.
"We don't ship a molecule. We ship a clinical outcome – wrapped in proof, scale and partnership."

– C. P. Bothra · Founder & Chairman

Award & Recognition

7th IPA ACG-SCITECH Innovation Awards 2020

Honoured with the Best Innovative Development of Solid Dosage Form in the industry – conferred during the 72nd Indian Pharmaceutical Congress (IPC) at Nagpur on 21st January 2023.

Memento + INR 1,00,000 cash prizePresented by IPA-ACG SCITECH72nd IPC · Nagpur

The winning innovation

Nanotechnology-based highly soluble curcumin oral drops

Stabicon nominated its nanotechnology-based highly soluble oral drops for the 7th IPA-ACG SCITECH Innovation Awards in December 2020. The oral route is the most common and cost-effective route for drug administration, yet it is limited by the physicochemical properties of many molecules – low aqueous solubility, instability, low permeability and rapid metabolism, all resulting in low and irregular oral bioavailability. Curcumin (diferuloylmethane), a polyphenol extracted from the 'golden spice' turmeric (Curcuma longa), offers a plethora of scientifically proven health benefits – yet its full potential has long been limited by poor solubility, poor bioavailability, chemical instability and crystalline nature. Stabicon's nano-engineered oral drops were honoured for solving exactly these challenges.

  • IPA is the apex body of pharmaceutical scientists & technologists in India
  • ACG SCITECH is promoted by Associated Capsule Group – India's largest hard-gelatin capsule manufacturer
  • Recognised for overcoming curcumin's poor solubility, stability & bioavailability
Our Group Companies

An ecosystem built around science, scale and last-mile trust.

The group's R&D engine

Lyrus Life Sciences

Focused on advanced drug delivery, nanotechnology and complex generics – driving innovation through proprietary platforms like C3 CURA™ and EzyDoses, enabling differentiated, high-performance therapies.

Established 2004 · Retail arm

Trust Chemists & Druggists

Ensures authentic medicines reach patients reliably. With 100+ hospital-based pharmacy outlets, it serves as the last mile of care while providing direct insights into patient needs and market demand.

Inside Stabicon

People, places & moments – a glimpse through the lens.

A curated look at our manufacturing floors, R&D benches, quality-control labs and cleanroom operations – the everyday rituals behind partner-grade output.

View full gallery (35)
Scientists in a Stabicon-aligned research environment
Five decades · Three companies

From Kanpha (1976) to Stabicon – the same scientific instinct, scaled across generations.

Group's Landmark Achievements

Five decades of first-to-market firsts.

01

Pioneered Market Leadership

Successfully developed and scaled the Indian version of Augmentin for SmithKline Beecham, achieving the No.1 brand position in India from its launch in 1999.

02

First-to-Market Innovation

Introduced Methenamine Hippurate and Ibuprofen Sodium tablets in India, demonstrating strong capability in identifying and commercialising differentiated products.

03

Global Market Execution

Experience in navigating multi-market regulatory, supply chain and commercialisation strategies across India and international markets.

04

Global Collaboration Excellence

Established and operated within a strategic partnership with SmithKline Beecham, working out of Beecham House, London, to drive international expansion initiatives including Africa.

05

End-to-End Commercialisation

Proven track record in product development, scale-up, manufacturing and lifecycle management of high-value pharmaceutical brands.

06

Sustained Brand Building

Demonstrated ability to convert scientific products into category-leading brands with long-term market dominance.

Why we are different

Six differentiators that shape every formulation we ship.

Proven Expertise

Built on 50+ years of pharma experience with strong scientific and regulatory foundations.

Science-Driven Naturals

Clinically supported ingredients with high safety and minimal chemical load.

Global, Scalable Quality

Stability-ready, clinically adaptable formulations with packaging and dose flexibility.

Platform-Led Approach

From ingredients to high-performance, bioavailable therapeutic platforms.

Selective Partnerships

Focused on science-driven collaborations, not mass-market distribution.

Flexible Dosage Innovation

Shots, Effervescents, Capsules, Oral melts, Tablets, Diskettes, Water, Tea & novel delivery platforms.

Core Capabilities

Five vertically integrated functions – from ideation to regulatory.

Formulation Research & Development

  • Global Nutraceutical Expertise – natural product development for international markets
  • Oral Solid Technologies – IR, SR, DR, CR & advanced release systems
  • Capsule Systems – multi-fill formats (powders, granules, pellets, capsule-in-capsule)
  • Powder Innovations – mouth-melt, ODT, suspension-ready formulations
  • Multi-Format Capability – topicals, liquid orals and nano-enabled delivery

Analytical Research & Development

  • Method Development & Validation – stability-indicating analytical methods
  • Method Transfer & Verification – scalable and reproducible across facilities
  • Degradation Studies – impurity profiling and stability assessment
  • Cleaning Validation – cross-contamination control and compliance
  • Regulatory Alignment – data integrity and full analytical lifecycle support

Quality, Stability & Advanced Analytics

  • Comprehensive QC Testing – HPLC, GC, UPLC, wet lab, dissolution
  • Microbiological Testing – limits, endotoxins, preservative efficacy
  • ICH Stability Studies – long-term, accelerated, controlled conditions
  • Special Stability – photo, thermal cycling, freeze-thaw, in-use
  • Advanced Capabilities – nitrosamines, elemental & genotoxic impurities; 1,38,000 L storage
Certifications

Audited and approved across seven global standards.

ISO/IEC 17025:2017 (NABL)WHO Geneva – Audited & ApprovedFSSAI ApprovedCDSCO IndiaUS FDA – Registered FacilityDSIR RegisteredAYUSH Registered

Accolades

Recognition built over five decades.

  • Awarded No.1 CMO in the Country
  • Manufacturer of 11 out of top 25 brands
  • One of only 3 commercial manufacturing facilities in India with WHO approval
  • IPA ACG-SCITECH Innovation Award 2020 – Solid Dosage Form Innovation
Stabicon Life Sciences

Science-Led Formulations. Scalable Health Platforms.

Offices

Corporate Office

22, 7th Cross, Jaibharath Nagar, Bengaluru 560 033, Karnataka, India

Research & Development

28, Bommasandra Industrial Area, 4th Phase, Jigani Hobli, Anekal Taluk, Bengaluru 560 099, Karnataka, India

Newsletter

Quarterly briefings on platforms, science & partnerships.

No spam. Unsubscribe in one click. Your email stays with us.

Press Kit

Logos, fact sheet & spokesperson bios – all in one download.

Download Press Kit (ZIP)

For media queries: press@stabicon.com

Accreditations

ISO/IEC 17025:2017 (NABL)WHO Geneva – Audited & ApprovedFSSAI ApprovedCDSCO IndiaUS FDA – Registered FacilityDSIR RegisteredAYUSH Registered

© 2026 Stabicon Life Sciences Pvt. Ltd. All rights reserved.

Science-Led Formulations. Scalable Health Platforms.